CoChat

A translational continuum of model systems for evaluating treatment strategies in Alzheimer’s disease: isradipine as a candidate drug

Open access
Copenhaver, Philip F., Anekonda, Thimmappa S., Musashe, Derek, Robinson, Kristine M., Ramaker, Jenna M., Swanson, Tracy L., Wadsworth, Teri L., Kretzschmar, Doris, Woltjer, Randall L., Quinn, Joseph F. · 2011 · Disease Models & Mechanisms
Cited by 44

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

SUMMARY: A growing body of evidence supports the ‘calcium hypothesis’ of Alzheimer’s disease (AD), which postulates that a variety of insults might disrupt the homeostatic regulation of neuronal calcium (Ca2+) in the brain, resulting in the progressive symptoms that typify the disease. However, despite ongoing efforts to develop new methods for testing therapeutic compounds that might be beneficial in AD, no single bioassay permits both rapid screening and in vivo validation of candidate drugs that target specific components of the Ca2+ regulatory machinery. To address this issue, we have integrated four distinct model systems that provide complementary information about a trial compound: the human neuroblastoma MC65 line, which provides an in vitro model of amyloid toxicity; a transgenic Drosophila model, which develops age-dependent pathologies associated with AD; the 3×TgAD transgenic mouse, which recapitulates many of the neuropathological features that typify AD; and the embryonic nervous system of Manduca, which provides a novel in vivo assay for the acute effects of amyloid peptides on neuronal motility. To demonstrate the value of this ‘translational suite’ of bioassays, we focused on a set of clinically approved dihydropyridines (DHPs), a class of well-defined inhibitors of L-type calcium channels that have been suggested to be neuroprotective in AD. Among the DHPs tested in this study, we found that isradipine reduced the neurotoxic consequences of β-amyloid accumulation in all four model systems without inducing deleterious side effects. Our results provide new evidence in support of the Ca2+ hypothesis of AD, and indicate that isradipine represents a promising drug for translation into clinical trials. In addition, these studies also demonstrate that this continuum of bioassays (representing different levels of complexity) provides an effective means of evaluating other candidate compounds that target specific components of the Ca2+ regulatory machinery and that therefore might be beneficial in the treatment of AD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1242/dmm.006841

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 44

Metadata

Authors
Copenhaver, P. F., Anekonda, T. S., Musashe, D., Robinson, K. M., Ramaker, J. M., Swanson, T. L., Wadsworth, T. L., Kretzschmar, D., Woltjer, R. L., & Quinn, J. F.
Venue
Disease Models & Mechanisms
Published
2011-09-01
Volume
4
Issue
5
Pages
634-648
ISSN
  • 1754-8403 (ISSN-L)
  • 1754-8411
OpenAlex
W2100421543
Cited by
44
References
15
FWCI
2.31
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A translational continuum of model systems for evaluating treatment strategies in Alzheimer’s disease: isradipine as a candidate drug. https://app.cochat.ai/papers/10.1242/dmm.006841
The paper
Copenhaver, P. F., Anekonda, T. S., Musashe, D., Robinson, K. M., Ramaker, J. M., Swanson, T. L., Wadsworth, T. L., Kretzschmar, D., Woltjer, R. L., & Quinn, J. F. (2011). A translational continuum of model systems for evaluating treatment strategies in Alzheimer’s disease: isradipine as a candidate drug. Disease Models & Mechanisms. https://doi.org/10.1242/dmm.006841

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.